|
|
Grail Inc
GRAL's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Grail Inc 's sales fell
by -74.65 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 2732
Medical Laboratories industry recorded
growth of revenues by 2.95 %
Grail Inc net loss decreased from $-2,027 millions, to $-106 millions in first quarter of 2025,
• More on GRAL's Growth
|
|
Grail Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 42.12 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
-0 |
|
PE TTM
|
|
Company's Price to Sales ratio is at 9.56.
Medical Laboratories industry's Price to Sales ratio is at 2.29.
• More on GRAL's Valuation
|
|
|
|
|
Grail Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 42.12 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
-0 |
|
PE TTM
|
|
Company's Price to Sales ratio is at 9.56.
Medical Laboratories industry's Price to Sales ratio is at 2.29.
Grail Inc Price to Book Ratio is at 0.62 lower than Industry Avg. of 157.06. and higher than S&P 500 Avg. of 0.01
• More on GRAL's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
